Valbenazine: Drug review
Valbenazine is the first drug approved by the US Food and Drug Administration for the treatment of adults with tardive dyskinesia (TD) on April 11, 2017. It acts as a reversible inhibitor of vesicular monoamine transporter 2. It is available orally with a starting dose of 40 mg once daily which can...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Annals of Indian Psychiatry |
| Subjects: | |
| Online Access: | http://www.anip.co.in/article.asp?issn=2588-8358;year=2017;volume=1;issue=2;spage=84;epage=87;aulast=Konwar |